for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Deciphera Pharmaceuticals Inc

DCPH.OQ

Latest Trade

49.25USD

Change

1.27(+2.65%)

Volume

35,944

Today's Range

48.52

 - 

49.89

52 Week Range

19.70

 - 

49.89

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
47.98
Open
48.52
Volume
35,944
3M AVG Volume
11.85
Today's High
49.89
Today's Low
48.52
52 Week High
49.89
52 Week Low
19.70
Shares Out (MIL)
51.04
Market Cap (MIL)
2,449.09
Forward P/E
-11.46
Dividend (Yield %)
--

Next Event

Deciphera Pharmaceuticals Inc at Jefferies London Healthcare Conference

Latest Developments

More

Deciphera Pharmaceuticals Reports Q3 Loss Per Share $1.28

Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation At ESMO 2019 Congress Demonstrating Positive Results From Invictus Pivotal Phase 3 Study Of Ripretinib In Patients With Advanc

Deciphera Pharmaceuticals Prices Public Offering Of 10.8 Mln Common Shares at $37/Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

Industry

Biotechnology & Drugs

Contact Info

200 Smith St

+1.781.2096400

https://www.deciphera.com

Executive Leadership

James Arthur Bristol

Independent Chairman of the Board

Steven L. Hoerter

President, Chief Executive Officer, Director

Daniel Lee Flynn

Founder, Executive Vice President, Chief Scientific Officer

Thomas J. Kelly

Chief Financial Officer, Executive Vice President, Treasurer

Stephen B. Ruddy

Chief Technology Officer

Key Stats

1.83 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-2.990

2018

-2.820

2019(E)

-4.264
Price To Earnings (TTM)
--
Price To Sales (TTM)
97.96
Price To Book (MRQ)
4.04
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.19
LT Debt To Equity (MRQ)
0.16
Return on Investment (TTM)
-33.63
Return on Equity (TTM)
-31.61

Latest News

Latest News

Deciphera shares skyrocket as cancer drug improves progression-free survival

Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study.

Deciphera Pharma's late-stage stomach cancer study meets main goal

Deciphera Pharmaceuticals Inc said on Tuesday its late-stage study met the main goal of progression-free survival in patients with a form of stomach cancer.

BRIEF-Deciphera Pharma Initiates Late Stage Study In Gastrointestinal Cancer Patients

* DECIPHERA PHARMACEUTICALS INITIATES PHASE 3 CLINICAL STUDY WITH DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (“INVICTUS” STUDY)

BRIEF-Deciphera Pharmaceuticals Announces Orphan Drug Designation From The EMA For DCC-2618 For The Treatment Of Gastrointestinal Stromal Tumors

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES ORPHAN DRUG DESIGNATION FROM THE EMA FOR DCC-2618 FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS Source text for Eikon: Further company coverage:

BRIEF-Deciphera Pharma reports data from ongoing phase 1 clinical study of DCC-2618 

* Deciphera Pharmaceuticals reports data from ongoing phase 1 clinical study of DCC-2618 at the 22nd annual scientific meeting and education day of the society for neuro-oncology Source text for Eikon: Further company coverage:

BRIEF-Deciphera Pharmaceuticals Q3 loss $5.85 per share​

* Deciphera Pharmaceuticals Inc announces third quarter 2017 financial results and corporate highlights

BRIEF-New Leaf Venture reports 12.9 pct stake in Deciphera Pharmaceuticals

* New Leaf Venture Management III LLC reports 12.9 percent stake in Deciphera Pharmaceuticals as of Oct 2 - SEC filing Source text:[http://bit.ly/2gwqdFF] Further company coverage:

BRIEF-Viking Global Investors reports 8.1 pct passive stake in Deciphera Pharmaceuticals

* Viking Global Investors LP reports 8.1 percent passive stake in Deciphera Pharmaceuticals LLC as of Oct 2 - SEC filing Source : (http://bit.ly/2z0WbAm) Further company coverage:

BRIEF-Deciphera Pharmaceuticals shares open 17.9 pct above IPO price in debut

* Deciphera Pharmaceuticals shares open at $20.05 in debut on NASDAQ vs IPO price of $17 per share Further company coverage:

BRIEF-Deciphera Pharmaceuticals prices initial public offering of 7.5 mln shares at $17 per share

* Deciphera Pharmaceuticals announces pricing of initial public offering

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up